Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ThisCART7 in Refractory or Relapsed T Cell Malignancies
NCT05127135Phase 1Unknown
- Sponsor
- Fundamenta Therapeutics Inc.
- Start
- Jan 2020
- Primary completion
- Jan 2023
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ThisCART7 in t-cell acute lymphoblastic leukemia (T-ALL), T-cell acute lymphoblastic lymphoma (T-LBL) and T-cell non-Hodgkin lymphoma, sponsored by Fundamenta Therapeutics Inc. Primary endpoint: Incidence of Treatment-related grade >= 3 Adverse Events or SAE at 4 weeks. Status: unknown.
02
Drugs
ThisCART7
03
Conditions
t-cell acute lymphoblastic leukemia (T-ALL)T-cell acute lymphoblastic lymphoma (T-LBL)T-cell non-Hodgkin lymphoma
Beyond the preview
Go deeper on NCT05127135.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05127135.